NCT02738008Phase 2Terminated

Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection

Study sponsor: Arrowhead Pharmaceuticals

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2016-12Actual
Enrollment · participants12Actual
Source updated2026-01-13Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.